Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-MUC16/CD28 bispecific antibody REGN5668

A bispecific monoclonal antibody against both the tumor-associated antigen (TAA) human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential antineoplastic and immunostimulating activities. Upon administration, anti-MUC16/CD28 bispecific antibody REGN5668 binds to both CD28 on T cells and MUC16-expressing tumor cells, which cross-links the T cells to the tumor cells. This may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells. MUC16, a member of the mucin family of glycoproteins, is overexpressed by several epithelial cancers, including ovarian cancer.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-MUC16 x anti-CD28 bispecific antibody REGN5668
MUC16xCD28 bispecific antibody REGN5668
Code name:REGN 5668
REGN-5668
REGN5668
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search